3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
Nivolumab
7
cemiplimab
6
Specimen Handling
5
HhAntag691
5
Radiotherapy
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Biopsy
4
sonidegib
3
pembrolizumab
3
CTLA-4 Antigen
3
relatlimab
2
prednylidene
2
deltacortene
2
daromun
2
Surgical Procedures, Operative
2
Standard of Care
2
Prednisone
2
Observation
2
Aminolevulinic Acid
2
tocilizumab
1
talimogene laherparepvec
1
poly ICLC
1
flt3 ligand protein
1
X-Rays
1
Watchful Waiting
1
Vitamin D
1
Tomography, Optical Coherence
1
Therapeutics
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
MAPRE1 protein, human
×
1 year
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled